David Reynolds

David Reynolds is the Founder & Non-Executive Director at AstronauTx and the CEO of LoQus23 Therapeutics Ltd, a biotech company focusing on DNA damage repair pathways for treating neurodegenerative diseases. Along with their roles at SV Health Investors and UCL as a Visiting Professor, David has a wealth of experience in leadership positions at companies like Pfizer and H. Lundbeck A/S. David holds a BA and PhD in Natural Sciences from the University of Cambridge.